(Q41217040)
Statements
1 reference
Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies (English)
1 reference
J P Armand
1 reference
Y M Extra
1 reference
G Catimel
1 reference
D Abigerges
1 reference
M Marty
1 reference
M Clavel
1 reference
1 October 1996
1 reference
1 reference
7
1 reference
8
1 reference
837-842
1 reference
Identifiers
1 reference
1 reference